Evaxion has completed the one-year extension of its phase 2 trial for the personalized cancer vaccine EVX-01, designed using its AI-Immunology™ platform. The trial showed a 75% Objective Response Rate in advanced melanoma patients, with durable benefits and no relapses at two years. Patients received EVX-01 combined with Keytruda® initially, then as monotherapy, allowing evaluation of both treatment modes. Three-year efficacy data is expected in the second half of 2026, potentially confirming the vaccine's long-term effectiveness and immune response durability.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Following a five-year antitrust lawsuit by Epic Games, Google will let Android users in the US download third-party apps directly from the Google Play Store starting July 22. This change comes after a court ruling that found Google's Play Store pract...
Ondo Global Markets reached $1 billion in total value locked (TVL) for tokenized stocks by May 2026, with projections to hit $5 billion by year-end. USDC, Circle's stablecoin, is the preferred settlement currency for these tokenized equities, favored...
